These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 31033068)

  • 21. Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28.
    Papp KA; Reich K; Blauvelt A; Kimball AB; Gooderham M; Tyring SK; Sinclair R; Thaci D; Li Q; Cichanowitz N; Green S; La Rosa C
    J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1098-1106. PubMed ID: 30838709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tildrakizumab in the treatment of moderate-to-severe hidradenitis suppurativa.
    Kok Y; Nicolopoulos J; Howard A; Varigos G; Kern J; Dolianitis C
    Australas J Dermatol; 2020 Nov; 61(4):e488-e490. PubMed ID: 32627843
    [No Abstract]   [Full Text] [Related]  

  • 23. A Review of Ixekizumab, an Anti-Interleukin-17A Monoclonal Antibody, for Moderate-to-Severe Plaque Psoriasis.
    Peranteau AJ; Turkeltaub AE; Tong Y; Nawas Z; Tyring SK
    Skin Therapy Lett; 2016 Nov; 21(6):1-6. PubMed ID: 27825174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Debut Of Inflammatory Bowel Disease Associated To Ixekizumab In Patient With Moderate, Difficult -To-Manage Psoriasis.
    Merino Gallego E; Gómez Torres K; Martínez Amate E
    Gastroenterol Hepatol; 2020 Dec; 43(10):622-623. PubMed ID: 32674878
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis.
    Zachariae C; Gordon K; Kimball AB; Lebwohl M; Blauvelt A; Leonardi C; Braun D; McKean-Matthews M; Burge R; Cameron G
    J Am Acad Dermatol; 2018 Aug; 79(2):294-301.e6. PubMed ID: 29653208
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psoriatic Plaques After Initiation of Dupilumab Therapy.
    DeGrazia TM; Raji K; Alshamekh S; Chisolm S
    Dermatitis; 2020; 31(4):e36-e37. PubMed ID: 32665517
    [No Abstract]   [Full Text] [Related]  

  • 27. Review of IL-17 inhibitors for psoriasis.
    Amin M; Darji K; No DJ; Bhutani T; Wu JJ
    J Dermatolog Treat; 2018 Jun; 29(4):347-352. PubMed ID: 29058501
    [No Abstract]   [Full Text] [Related]  

  • 28. Spesolimab use in generalised pustular psoriasis flares.
    Osborne S; Thacker S; Kam O; Wescott R; Wu JJ
    Lancet; 2024 Aug; 404(10455):846-847. PubMed ID: 39216967
    [No Abstract]   [Full Text] [Related]  

  • 29. Alemtuzumab and chronic plaque psoriasis.
    Aslam A; Marsland AM; Rog D; Griffiths CE
    Br J Dermatol; 2013 Jul; 169(1):184-6. PubMed ID: 23834118
    [No Abstract]   [Full Text] [Related]  

  • 30. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
    Vu TT; Gooderham M; Papp K
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spesolimab use in generalised pustular psoriasis flares - Authors' reply.
    Lebwohl MG; Thoma C; Haeufel T
    Lancet; 2024 Aug; 404(10455):847-848. PubMed ID: 39216969
    [No Abstract]   [Full Text] [Related]  

  • 32. Ustekinumab associated with flares of psoriatic arthritis.
    Stamell EF; Kutner A; Viola K; Cohen SR
    JAMA Dermatol; 2013 Dec; 149(12):1410-3. PubMed ID: 24132520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concurrent Atopic Dermatitis and Psoriasis Successfully Treated With Brodalumab.
    Gambardella A; Licata G; De Rosa A; Pagliuca F; Calabrese G; Alfano R; Argenziano G
    Dermatitis; 2021 Oct; 32(1S):e86-e88. PubMed ID: 33208631
    [No Abstract]   [Full Text] [Related]  

  • 34. Secukinumab-induced pompholyx in a psoriasis patient.
    Eichhoff G
    Dermatol Online J; 2020 Apr; 26(4):. PubMed ID: 32621689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world single-center experience with 10 cases of generalized pustular psoriasis successfully treated with ixekizumab.
    Nagata M; Kamata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Sugiura K; Tada Y
    J Am Acad Dermatol; 2020 Mar; 82(3):758-761. PubMed ID: 31560979
    [No Abstract]   [Full Text] [Related]  

  • 36. A scientific debate: key clinical questions in the management of psoriasis.
    Stingl G
    J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():1. PubMed ID: 22758910
    [No Abstract]   [Full Text] [Related]  

  • 37. Long-term continuation with secukinumab in psoriasis: association with patient profile and initial psoriasis clearance.
    Ferrières L; Konstantinou MP; Bulai Livideanu C; Hegazy S; Tauber M; Amelot F; Paul C
    Clin Exp Dermatol; 2019 Oct; 44(7):e230-e234. PubMed ID: 31055846
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The evolving role of biologics in the treatment of pediatric psoriasis.
    Luu M; Cordoro KM
    Skin Therapy Lett; 2013 Feb; 18(2):1-4. PubMed ID: 23508772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of anti-IL 17A for psoriasis is not necessarily contraindicated in organ transplantation patients.
    Di Altobrando A; Lacava R; Patrizi A; Sacchelli L; La Manna G; Comai G; Bardazzi F
    Eur J Dermatol; 2020 Jun; 30(3):311-313. PubMed ID: 32540794
    [No Abstract]   [Full Text] [Related]  

  • 40. Mild therapeutic response of alopecia areata during treatment of psoriasis with secukinumab.
    Pagnanelli G; Cavani A; Canzona F; Mazzanti C
    Eur J Dermatol; 2020 Oct; 30(5):602-603. PubMed ID: 33185532
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.